Here's Why Shareholders May Want To Be Cautious With Increasing Ikena Oncology, Inc.'s (NASDAQ:IKNA) CEO Pay Packet
Key Insights Ikena Oncology will host its Annual General Meeting on 7th of June CEO Mark Manfredi's total compensation includes salary of US$569.0k The total compensation is 44% higher than the av
It's Unlikely That Ikena Oncology, Inc.'s (NASDAQ:IKNA) CEO Will See A Huge Pay Rise This Year
Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It 'Disappointing'
On Tuesday, Ikena Oncology Inc (NASDAQ:IKNA) discontinued the clinical IK-930 program, the company's TEAD1- selective Hippo pathway inhibitor, and continued clinical development of IK-595, a novel MEK
Wedbush Downgrades Ikena, Cites Discontinuation of Lead Asset
Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bank of Montreal (NYSE:BMO) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter financial results.Bank of Montreal posted quarterly adjusted
This American Airlines Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Wedbush ana
Semler Scientific, Genetic Technologies, ReShape Lifesciences Among Healthcare Movers
Ikena Oncology Cut to Neutral From Outperform by Wedbush
Ikena Oncology Cut to Neutral From Outperform by Wedbush
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersReshape Lifesciences (NASDAQ:RSLS) shares increased by 82.9% to $0.38 during Wednesday's pre-market session. The market value of their outstanding shares is at $8.9 million. Scorpius Holdings (
TD Cowen Sticks to Its Buy Rating for Ikena Oncology (IKNA)
Ikena Oncology Is Maintained at Buy by HC Wainwright & Co.
Ikena Oncology Is Maintained at Buy by HC Wainwright & Co.
Express News | Ikena Oncology, Inc. : H.c. Wainwright Cuts Target Price to $4 From $11
Wedbush Downgrades Ikena Oncology to Neutral From Outperform After Discontinuation of Lead Program IK-930, Adjusts PT to $2 From $8
Wedbush Downgrades Ikena Oncology to Neutral From Outperform After Discontinuation of Lead Program IK-930, Adjusts PT to $2 From $8.
Express News | Ikena Oncology Inc : Wedbush Cuts to Neutral From Outperform; Cuts Target Price to $2 From $8
Stocks to Watch: Ooma, Faraday Future Intelligent Electric, Ikena Oncology
By Ben Glickman Ooma raised its full-year outlook for adjusted earnings after the online-communications company's revenue and loss were ahead of analysts' expectations. The company's cash flow from o
Express News | Ikena Oncology - Announced Restructuring Plan and Board's Approval of a Process to Explore, Review and Evaluate a Range of Potential Strategic Options
Express News | Ikena Oncology Inc - Following Restructuring Plan, Company Expects to Have Approximately 16 Full-Time Employees
Express News | Ikena Oncology Inc - Restructuring Plan Will Result in Termination of About 18 Employees and Is Expected to Be Completed in Q3 of 2024
Express News | Ikena To Reduce Workforce By ~53%
Express News | Ikena Oncology Shares Are Trading Higher After the Company Announced It Will Discontinue Development of IK-930 and Evaluate Strategic Options for Both the Company and Its Development Pipeline
No Data